Publications by authors named "Michael Albani"
We report on a 6-month-old boy with craniosynostosis, pseudohypoparathyroidism type 1a (PHP1A), and a GNAS gene mutation. He had synostoses of the coronal, frontal, and sagittal sutures, brachyturricephaly, and hydrocephaly. He also had congenital hypothyroidism, round face, full cheeks, shortness of limbs, mild developmental delay, and muscular hypotonia.
View Article and Find Full Text PDFArticle Synopsis
- Continuous oral treatment with topotecan may be more effective for pediatric patients with recurrent high-grade glioma compared to standard treatment schedules, but there's limited experience in this group and increased side effects were noted in adults.
- A study with 32 children (median age 9.5 years) focused on determining the maximum tolerated dose by administering the drug daily, using individual patient dosing protocols to evaluate blood plasma levels.
- Results indicated that the maximum tolerated dose was 0.9 mg/m² per day, with some efficacy observed in a small number of patients, highlighting that while the treatment was generally well tolerated, its effectiveness was limited.